Report
Oussema Denguir

AstraZeneca : Q2 2018e: last quarter of pain before the new growth story?

>Our adjustments: positive product newsflow, +550p on our target price - Ahead of AZN’s Q2 2018 results publication on Thursday 26 July next, we updated our model, which led us to increase our target price to 6,250p (vs 5,700p). We therefore reiterate our Buy recommendation. Our changes take into account the (mainly positive) product newsflow in Q2 2018: we therefore increase our PoS from 70% to 100% for Lokelma in the treatment of hyperkalemia following its approval ...
Underlying
AstraZeneca PLC

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch